Autopsy report · NCT00652899

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

“Withdrawn due to toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 5 months before it stopped.
• 14 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer

Interventions

Allopurinol; Cyclophosphamide; Fludarabine phosphate; total-body irradiation; Allogeneic natural killer cells; Aldesleukin

Participants

14

Sites

1

Countries

United States

Trials that died the same way

• SMMART Adaptive Clinical Treatment (ACT) Trial
  “Withdrawn due to a change in therapeutic interventions.” (74% match in meaning)
• The Effect of Light Therapy on Post-Surgical Pain
  “Withdrawn due to lack of resources” (72% match in meaning)
• Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
  “drug withdrawn from market” (70% match in meaning)
• The Sub-Sero Study
  “Drug supply withdrawn (dec 2019)” (69% match in meaning)
• Lapatinib and Bortezomib in Patients With Advanced Malignancies
  “Drug support withdrawn” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.